Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 4/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789605 | 0.92 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL6784822 | 0.89 | TDP1 (0.48) | RAB9ASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL6784915 | 0.83 | KMT2A (0.57) | MEN1KMT2ACASP3SENP7SENP8 | |
| SCHEMBL6787909 | 0.82 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL6781577 | 0.76 | KMT2A (0.58) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL28438951 | 0.71 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14349697 | 0.71 | HCAR2 (0.64) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2273299 | 0.71 | KDM4E (0.61) | RAB9ASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL7964170 | 0.70 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL2229842 | 0.69 | NPC1 (0.76) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| EP-1261321-A2 | CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001007020-A2 | CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | RAB9A 2130/4885NPC1 3387/4885SMN1; SMN2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.